Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22030700 | 0.91 | KCNA5 (0.32) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20557547 | 0.89 | KCNA5 (0.33) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5253690 | 0.89 | KCNA5 (0.35) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4697841 | 0.88 | KCNA5 (0.32) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4697845 | 0.88 | KCNA5 (0.32) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4696891 | 0.85 | KCNA5 (0.33) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4696887 | 0.85 | KCNA5 (0.33) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20557817 | 0.84 | KCNA5 (0.36) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2066952 | 0.84 | KCNA5 (0.36) | KCNA5POLBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20557778 | 0.84 | PLA2G10 (0.39) | KCNA5POLBCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3630111-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Entasis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018208769-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | KCNA5 1510/4885POLB 2645/4885CYP3A4 1679/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | KCNA5 1510/4885POLB 2645/4885CYP3A4 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.